TEAM / ADVISORS

Mr. Thomas has been working alongside leading authorities in the field of Performance Medicine specializing in Intravenous Nutrient Therapy (IVNT) and NAD+ for 7 years. He has spent the last 5 years as CEO of Performance Medical Technologies investigating the clinical market for NAD+ and developing relationships with hundreds of physicians, patients, researchers, and FDA/EMA regulatory experts. Prior to serving as CEO for PMT, Mr. Thomas held Senior Business Development positions for 10 years in various high growth companies including digital marketing/e-commerce, large scale fixed cost analysis, and logistics. Mr. Thomas holds a Bachelor’s of Science Degree in Business Administration from the College of Charleston with a concentration in Entrepreneurship and recently completed the Pharmaceutical Management Program at Cornell University.

Mr. Wassenaar is a serial technology entrepreneur and investor with PMT being his 9th startup. Mr. Wassenaar was most recently the cofounder and CEO of Medical Automation Systems (MAS) in Charlottesville, VA which revolutionized point of care diagnostic data systems in partnership with Roche Diagnostics, J&J Lifescan, Alere, and Abbott Diagnostics among others. MAS was sold to the Alere Corporation in 2012, and subsequently sold as the core of Abbott’s Center for Global Informatics and continues to operate in Charlottesville, VA.
Mr. Wassenaar was also the co-founder and CEO of the Epsilon Group which focused on large scale bioinformatic analytics and developed the first “in-silico” FDA approved modeling system for type I and II diabetes clinical trials and the analytical software for the UVA affiliated artificial pancreas project. He was also the co-founder and CEO of Computational Diagnostics which developed the first FDA approved non-invasive test for neonatal sepsis. Mr. Wassenaar is co-founder and CEO of Vibethink Corporation which is a digital media and software company, and the former co-founder and CEO of Clinical Information Sciences which developed physician clinical decision systems using evidence-based medicine. Mr. Wassenaar was the Chief Architect for the University of Virginia Medical Center and also Associate Professor of Architecture and Director of Research for the UVA School of Architecture. He holds a BSc. Degree from the University of Michigan with Chemistry and Computer Science majors and a March degree from the University of Michigan with a concentration in advanced hospital and technology facilities.

Dr. Fairchild has 27 years of experience practicing in Family Medicine, Integrative Medicine, and Addiction Medicine. Her practice is best described as “Genomic and Orthomolecular Integrative Medicine”, delivering personalized care through genomic analysis and lab testing of vitamins, minerals, and hormones coupled with addressing lifestyle and dietary issues. Dr. Fairchild graduated from Drexel University College of Medicine in 1997 and received her fellowship in Integrative Medicine from the University of Kansas Medical Center (KUMC) in 2012.

Ms. Barton completed her Master’s Degree in Clinical and Translational Research with a focus in neurodegenerative diseases and clinical trials from Georgetown University in May 2024. Currently, Ms. Barton serves as a Research Assistant to Moshe Levi, MD, Interim Dean for Research at Georgetown researching NAD+ related technology relative to Alzheimer’s Disease and other neurodegenerative diseases. Prior to enrolling at Georgetown, Ms. Barton served as a Research Technician at Columbia University Medical Center in the Department of Pathology and Cell Biology studying and evaluating pathogenesis of Essential Tremor, performing postmortem neuroimaging studies, and various quantitative analyses for clinically relevant anatomical biomarkers. Ms. Barton received her Bachelor of Science degree from Roanoke College in 2021 in Biology and Neuroscience.

Mr. Evanow spent 15 years as a Vice President for Salesforce in San Francisco, CA and co-founded the Health and Life Sciences vertical, which is today a $1B vertical at Salesforce. In addition, he worked with Twilio as a Director managing the Public Sector government vertical. Mr. Evanow has consulted and partnered with many HLS, Biotech, and Pharma research entities such as Genentech/Roche, McKesson, Bio-Rad, Gilead Sciences, ARUP Laboratories at the University of Utah, Johns Hopkins University Medicine and Stanford Health Care. In addition, he worked with Payer/Provider companies and Federal agencies across the U.S. including Blue Shield of California, Kaiser Permanente, Veterans Affairs (VA) hospital system, National Institute of Health (NIH), CDC and the HHS. Mr. Evanow holds a Bachelor’s of Science Degree from the University of Virginia and an International MBA from the Thunderbird School of Global Management, now a part of Arizona State University.

Dr. Kim is the founder and CEO of Oak Bioinformatics, a groundbreaking bioinformatics company dedicated to broadening the access and understanding of genomic data across academia and industrial biological sciences. Serving as lead developer of various genomic related data science projects for over 16 years, Dr. Kim is regarded as one of the leading bioinformatic data engineers in the Commonwealth of Virginia. Dr. Kim earned a Bachelor’s Degree and PhD in Biotechnology, and a Master’s Degree in Bioengineering and Biomedical Engineering from Seoul National University in Korea.

Dr. Broom Gibson serves as the co-chair and lead data scientist for NAD Research Inc. and is an Associate Professor of Psychology in the School of Natural and Behavioral Sciences at William Carey University in Hattiesburg, MS. Dr. Broom-Gibson has co-authored multiple case studies on the effect of intravenous NAD+ treatment for patients with Parkinson’s Disease and alcohol use disorder.

Dr. Broom Gibson received her PhD in experimental psychology from the University of Mississippi in 2002 and completed research associate/fellowship positions at Boston University School of Medicine and Tulane University School of Medicine.

Prof. Norman Moore completed his undergraduate studies in Medicine at Queen’s University, Ireland in 1964. He received his MD degree in the same university and received training in Psychiatry at the Royal Air Force, London. Prof. Moore attended the program for Advanced Training in Biomedical Research Management in Harvard School of Public Health. Prof. Moore holds four honors from American Psychiatric Association and Royal College of Psychiatrists. He also received the awards of “Mental Illness Research”, “Exemplary Psychiatrist”, “Distinguished Researcher of the Year” and “Recognition for Excellence in Medical Student Education”.

Prof. Norman has taken part in the management of several professional associations. He was the scientific advisor for “Numology” and “Neuronetrix” biotechnical companies.  He was the Chief Editor of Clinical EEG and Neuroscience, and served as a member of the editorial boards of “Journal of Primary Care Psychiatry”, “Clinical EEG and Neuroscience” and “International Journal of Neural Systems”. Prof. Moore who has written more than 90 articles so far was awarded the Honorary Doctorate Degree by the Üsküdar University Senate in 2017.

European based global consultant focused on ensuring data integrity and patient safety providing clients with knowledge of the intricacies and complexities of regulatory matters. Mr. Stegman’s experience includes 6 years at the FDA as a Bioresearch Monitoring Specialist, leading teams of inspectors of Contract Research Organizations, Sponsors, and Bioclinical Research Facilities and also performing joint inspections/audits with foreign regulatory agencies (i.e., EMA, MOH, AIFA, etc.) enforcing both ICH and FDA regulations.

Prior to serving as Bioresearch Monitoring Specialist, Mr. Stegman served 5 years as investigator for the FDA. In this role, Mr. Stegman conducted more than 100 GCP, GMP, Dietary Supplement inspections of manufacturing and distribution firms, determined firms compliance with their respective regulations and assisted in determining the actions taken by FDA, and trained newly hired FDA Consumer Safety Officers.

Mr. Stegman’s specialties include: Clinical Research Management, Drug cGMPs, IND, NDA, and Dietary Supplement cGMPs.

Dr. Jackson holds a Master of Science (2005) and Doctor of Philosophy in Biochemistry and Molecular Biology (2013) from the University of Georgia and is a leading expert in Drug Discovery, Biochemistry, and Molecular Biology. Dr. Jackson served as the Director of Biological Sciences and Data Management at Lanier Biotherapeutics from 2021-2023, and led the development of first-in-class biologics in multi-functional retina, type 2 inflammation, dermatology and immune-oncology. Through de-risking the company’s lead programs and assessing manufacturability through the design and execution of preclinical studies (In vivo and Ex Vivo), biophysical characterization, and animal safety studies, Dr. Jackson facilitated the curation of a pre-IND packet for Lanier’s parent companies Biophta and Abeome Corporation.

Prior to serving at Lanier, Dr. Jackson held various senior scientific research roles at Abeome developing therapeutics. Dr. Jackson’s expertise includes CRO and CDMO contracting alliance and management, quality assurance supervisor, presentations to investors and pharmaceutical companies, patent application and processing, commercial packaging, shipping and quality control, enzymatic activity assays, mouse models for pharmacokinetics, genetically modified mouse models, and ability to manage cross-functional program team and act as scientific lead for drug development programs.